newsfilter
← Latest News
GlobeNewswire·

Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

  • Genelux Corporation appointed Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026.
  • Dr. Litten will oversee clinical development & medical strategy as Genelux advances Olvi-Vec through pivotal milestones in ovarian & lung cancer.
  • Dr. Litten brings over 20 years of experience leading clinical trials from Phase 1 to 4 in oncology across academia, large pharma, & biotech firms.
  • Most recently, he served as CMO at Chimeric Therapeutics, Ltd., & previously held CMO roles at Artiva Biotherapeutics, Inc. & senior positions at Juno Therapeutics, Clovis Oncology, & Amgen Inc.
  • Dr. Litten holds an M.D. from Emory University School of Medicine & a B.S. in Finance & Economics from Cornell University.
  • In connection with the appointment, Dr. Litten received a stock option inducement award for 275,000 shares vesting over four years.
  • Genelux is currently evaluating Olvi-Vec in three clinical trials: a Phase 3 trial for platinum-resistant ovarian cancer (OnPrime/GOG-3076), a Phase 2 trial for non-small-cell lung cancer (VIRO-25), & a Phase 1b dose-selection trial for small-cell lung cancer in China (Olvi-Vec-SCLC-202).
  • The company utilizes its proprietary CHOICE™ platform to develop oncolytic vaccinia virus immunotherapeutic product candidates.